A randomized, double-blind, placebo controlled, multi-centre, exploratory, pilot, phase II trial of 150 mg atacicept given subcutaneously in combination with rituximab in subjects with rheumatoid arthritis.

Trial Profile

A randomized, double-blind, placebo controlled, multi-centre, exploratory, pilot, phase II trial of 150 mg atacicept given subcutaneously in combination with rituximab in subjects with rheumatoid arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2017

At a glance

  • Drugs Atacicept (Primary) ; Rituximab
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Acronyms August III
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
    • 09 Jun 2012 Planned number of patients changed from 54 to 90 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top